Study finds DNA changes may flag blood cancer progress years early

DNA patterns may show whether some blood cancers are advancing years before standard tests catch the change, according to research summarized by Fox News.

A study published in Cancer Discovery by the American Association for Cancer Research followed 30 people with myeloproliferative neoplasms, or MPNs. In these diseases, bone marrow makes too many blood cells. Researchers tracked DNA in blood and bone marrow for genetic changes and compared those shifts with blood counts, stable disease, or progression to myelofibrosis or acute leukemia.

People who stayed stable often had stable DNA without cancer-related genetic changes. That pattern suggests a genetically quiet MPN is more likely to remain stable. Patients who progressed tended to show accumulating mutations over time, Fox News reported from the study findings.

The work is early and based on a small group. It does not create a consumer screening test for healthy people. It points toward closer molecular monitoring for patients already living with these chronic blood cancers, which are more common with age.

Standard care still relies on blood counts, symptoms, physical exams, and, when needed, bone marrow studies. The new research asks whether serial genetic profiling could give doctors an earlier warning when a quiet disease starts to change.

Fox News noted the broader hope that genetic warning signs could appear years before conventional markers move. For older patients, earlier notice could mean closer follow-up, clinical trial options, or treatment changes before acute leukemia develops.

Experts will need larger studies to confirm which mutations matter most, how often to test, and whether acting on DNA changes improves survival or quality of life. Cost and access will also matter if such monitoring moves from research labs into routine hematology clinics.

Anyone with an MPN diagnosis should keep scheduled appointments and discuss new research with a hematologist rather than seeking unproven commercial genetic panels on their own.